PACIRA BIOSCIENCES INC (PCRX:NASDAQ)
$25.4 -0.2 (-0.7813%)
Analysed PACIRA BIOSCIENCES INC (PCRX:NASDAQ) News Sources
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
30-06-2026
yahoo.com
Update: US Equity Indexes Rise as Semiconductors Lift Technology; Crude Oil Slips as Trump's Envoys in Qatar for Indirect Talks
30-06-2026
yahoo.com
Top Midday Decliners
30-06-2026
yahoo.com
Sector Update: Healthcare Stocks Softer Late Afternoon
30-06-2026
yahoo.com
Update: S&P 500, Nasdaq Composite Close Strongest Quarter in Six Years Amid Gains in Technology, Decline in Crude Oil
30-06-2026
yahoo.com
Zimmer Biomet to acquire iovera device from Pacira for $140m
01-07-2026
medicaldevice-network.com
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
01-07-2026
yahoo.com
Zimmer Biomet (ZBH) Is Buying Pacira’s Iovera Device And Expanding Into Spasticity
02-07-2026
yahoo.com
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare
02-07-2026
yahoo.com
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08-07-2026
yahoo.com
What is the current price of PACIRA BIOSCIENCES INC (PCRX:NASDAQ)?
The current price of PACIRA BIOSCIENCES INC (PCRX:NASDAQ) is $25.4.
PACIRA BIOSCIENCES INC (PCRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of PACIRA BIOSCIENCES INC (PCRX:NASDAQ) since the previous trading day is $-0.2.
PACIRA BIOSCIENCES INC (PCRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of PACIRA BIOSCIENCES INC (PCRX:NASDAQ) since the previous trading day is -0.7813%.
What is the most recent average sentiment score for PACIRA BIOSCIENCES INC (PCRX:NASDAQ)?
The most recent average sentiment score for PACIRA BIOSCIENCES INC (PCRX:NASDAQ) is 55 out of 100.
What is the most recent average sentiment for PACIRA BIOSCIENCES INC (PCRX:NASDAQ)?
The most recent sentiment for PACIRA BIOSCIENCES INC (PCRX:NASDAQ) is .
SEC-8K** Filing Available For PACIRA BIOSCIENCES INC (PCRX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.